Laserscope announced today that it has been issued an important U.S. patent from the United States Patent and Trademark Office (USPTO) relating to the use of its Photoselective Vaporization (PV) me
Oncolytics Biotech Inc. has been granted U.S. Patent 6,994,858 entitled "Reovirus Clearance of Ras-Mediated Neoplastic Cells from Mixed Cellular Compositions." The claims describe me
Connetics Corporation, a specialty pharmaceutical company that develops and commercializes dermatology products, announced today that on May 4, 2004
Sentillion, Inc., the leading provider of identity and access management (IAM) solutions for the always-on healthcare industry, has received its third patent (U.S. Patent No. 6,993,556) from the Un
Angiotech Pharmaceuticals has announced that it intends to appeal a UK trial court decision to revoke Angiotech's UK designation of its European Patent No. 0,706,376. The UK trial court rule
Takeda Pharmaceutical Company Limited and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc. have announced that Takeda's intellectual property rights have been successfully assert
On Friday, the U.S. District Court in Denver, Colorado, dismissed the patent infringement lawsuit filed by Medtronic against BrainLAB in 1998. The Court ruled that, as a matter of law, BrainL
GenoMed announced today that it received its second patent (US Patent #6,998,404) for the "Treatment or prevention of acute renal failure." Acute kidney failure usually happens when a patient gets deh
AstraZeneca announced today that it has filed a lawsuit in the United States District Court for the District of New Jersey against IVAX Corporation, IVAX Pharmaceuticals and Zenith Laboratories
While-you-wait medical tests that screen patients for thousands of disease markers could be possible with compact-disk technology patented by Purdue University scientists. A team led by physicist Da
Issued on August 24, 2004, the patent covers the new technology of Twinheads(R) which uses two or more shock wave sources in the extracorporeal shock wave lithotripsy; the non invasive treatment of kidney and ureteric stones. Further patents are pending.
"We are extremely pleased to be awarded patent 6,780,161. It presents us with a powerful new tool to reach a leading position within the Urological Stone Treatment market. It will also provide protection against whoever is trying to copy our Twinheads technology," said Dr. Yousry Faragalla, CEO of FMD, LLC.
About Twinheads FMD Twinheads provides distinguished improvement in stone fragmentation as has been found in research published in the Journal of Endourology in December 2001 and Journal of Urology in December 2003. Furthermore, the treatment with Twinheads has proved to be less injurious to tissues and to cause less adverse effects. This was confirmed by research by Dr. Ralph Clayman et al on its effect on animal tissue that was published in Urology in November 2003. More research by Dr. K. Sheir et al, to be published very soon in the British Journal of Urology, will show the first clinical results. Many urologists believe that the new Twinheads technology will lead the market to replace the older, more injurious and less effective lithotripters.
The Twinheads device was cleared by the FDA in May 2003. It was developed and is manufactured by FMD in its Lorton, Virginia headquarters. Further research aiming to study the use of Twinheads in tissue and tumor ablation is in development at the present time.
http://www.fmdco.com/